

7 August 2014

Fingolimod (Gilenya)

PHARMAC is proposing to list fingolimod (Gilenya) on the Pharmaceutical Schedule for patients with relapsing-remitting multiple sclerosis.

- Fingolimod (Gilenya) would be listed in Section B and Part II of Section H of the Pharmaceutical Schedule from 1 November 2014 at the following price and subsidy (ex-manufacturer, excluding GST):

Chemical	Presentation	Brand	Strength	Pack size	Price and subsidy
Fingolimod	Capsule	Gilenya	0.5 mg	28	\$2,650.00

- A confidential rebate would apply to Gilenya which would reduce the net price of the treatment.
- Gilenya would have subsidy and delisting protection until 31 October 2017.
- Fingolimod would be listed subject to access criteria in Section B and Part II of Section H of the Pharmaceutical Schedule:

Further background information

PHARMAC is also consulting on a separate proposal to:

- list another new MS treatment, natalizumab (Tysabri) on the Pharmaceutical Schedule; and
- amend funding restrictions for the currently listed MS treatments:
 - interferon-1-alpha (Avonex);
 - interferon beta-1-beta (Betaferon); and
 - glatiramer acetate (Copaxone).

For further detail on the overall proposal involving MS treatments, including the proposed access criteria that would apply to all five MS treatments including fingolimod, please refer to the MS treatments proposal consultation which can be found on our website at:

www.pharmac.health.nz/news/consultation-2014-08-07-mstreatments